UNSPSC 51281823: Mitoxantrone hydrochloride

This classification denotes an anthracenedione-derived antineoplastic agent, analgesic, and anthraquinone with the molecular formula C22H28N4O6.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier U6USW86RD0, chemically known as 9,10-anthracenedione, 1,4-dihydroxy-5,8-bis((2-((2-hydroxyethyl)amino)ethyl)amino)- (9ci) but more generally known as mitoxantrone hydrochloride, which bears US NIH Compound Identifier 4212.

UNSPSC 51281823 Mitoxantrone hydrochloride is a Commodity code for a specific chemotherapy pharmaceutical, yet the recent state and local opportunities tagged under this code do not reflect mitoxantrone procurement. Instead, the posted solicitations involve naloxone (an opioid antagonist), safe drug deactivation systems, doxycycline hyclate, and ciprofloxacin hydrochloride — none of which are mitoxantrone or closely related oncology drugs. This mismatch suggests the code shows little relevant recent activity aligned with its nominal scope.

The Illinois Department of Public Health awarded a pharmaceutical warehouse piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC in August 2026 for doxycycline and ciprofloxacin supply under an Invitation for Bid process, with a total award of $2,999,999.11 over the contract life including renewals. Seminole County, Florida issued an IFB in June 2026 for 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries required and a two-year initial term plus one-year renewal option. Neither opportunity directly reflects mitoxantrone procurement or the chemotherapy use case this code nominally describes. The issuing bodies are a state health department and a county government, both using cooperative purchasing and traditional IFB processes. Without substantive recent solicitations for mitoxantrone itself under this code, the procurement signal for this specific pharmaceutical remains unclear.